ArticleMolecular therapy. Oncology2026

Targeting SMYD2 improves immunotherapy response in experimental hepatocellular carcinoma.

Bárbara Bueloni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.